Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 14/20 | 0.80 |
| ▸ | SCN5A | Q14524 | 13/20 | 0.80 |
| ▸ | SCNN1A | P37088 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.54 |
| ▸ | AR | P10275 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4627561 | 0.94 | SCN2A (0.80) | SCN2ASCN5ASCNN1AALDH1A1KMT2A | |
| SCHEMBL4629193 | 0.90 | SCN5A (0.83) | SCN2ASCN5ASCNN1AALDH1A1CACNA1H | |
| SCHEMBL4629278 | 0.89 | SCN2A (1.00) | SCN2ASCN5AALDH1A1CACNA1H | |
| SCHEMBL4628723 | 0.85 | SCN5A (1.00) | SCN2ASCN5ASCNN1A | |
| SCHEMBL4628381 | 0.84 | SCN5A (0.98) | SCN2ASCN5ASCNN1A | |
| SCHEMBL4629272 | 0.83 | SCN2A (1.00) | SCN2ASCN5AALDH1A1 | |
| SCHEMBL4628697 | 0.83 | SCN2A (0.84) | SCN2ASCN5AALDH1A1MAPTKDM4E | |
| SCHEMBL4629257 | 0.83 | SCN2A (0.94) | SCN2ASCN5AKMT2AMAPTMEN1 | |
| SCHEMBL4627417 | 0.82 | SCN5A (1.00) | SCN2ASCN5AKMT2AMAPTMEN1 | |
| SCHEMBL4628959 | 0.81 | SCN2A (0.88) | SCN2ASCN5AKMT2AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1918272-A1 | Pharmaceutically active compounds and methods of use | Wyeth a Corporation of the State of Delaware (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| US-7041702-B1 | Pharmaceutically active compounds and methods of use | SCION PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270741-A1 | Pharmaceutically active compounds and methods of use | GBA1, CTSA, GAA | SCN2A 1613/4885SCN5A 1196/4885SCNN1A 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.